| Price | $205.55 |
| Year Range | $75.96 – $206.97 |
| Market Cap | $44.1B |
| Industry | Biotechnology |
What Is Revolution Medicines’s AI Stock Analysis?
Revolution Medicines’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Revolution Medicines’s momentum in near-real time.
Revolution Medicines (RVMD) has an AltIndex AI Score of 68/100, currently a Buy signal. The AI Score distills Revolution Medicines's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Revolution Medicines’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Revolution Medicines — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving RVMD’s AI Score?
Fundamentals
Net income for the last quarter was $-454M. This represents a decrease of 24.37% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 112.64%, which may be a cause for concern. Ebitda for the last quarter was $-441M. This represents a decrease of 26.54% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 85.91%, which may be a cause for concern. In the last couple of months, there's been a couple of company insiders selling their stock, a potentially bearish signal.
See Revolution Medicines’s earnings and insider transactions.
Technicals
Today's stock price is $205.55. This is an increase of 9.99% compared to a month ago, indicating a positive short-term trend. Compared to a year ago, there is an increase of 469.86%, suggesting a positive long-term trend. The trend is bullish. The current SMA10 is $198.65, which is higher than the previous SMA10 of $196.85. This indicates a potential upward trend in price movement. The RSI is 67.9, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
Revolution Medicines has an estimated 148 open positions. This number is up by 38% in the last couple of months, indicating a company that looking to grow and expand. Potentially a healthy sign. The business outlook among employees at Revolution Medicines is very high (an estimate of 90% of employees have a positive outlook), a positive sign. Revolution Medicines has an estimate of 110,000 visitors to their webpage, with no meaningful increase or decrese in the last couple of months.
Explore Revolution Medicines’s job postings, web traffic and app downloads.
Sentiment & social
The sentiment for the stock on various stock forums is high, a positive sign.
Track Revolution Medicines’s market sentiment.
Frequently Asked Questions: Revolution Medicines AI Stock Analysis
Revolution Medicines's AltIndex AI Score is 68/100, currently a Buy signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Revolution Medicines a Buy (68/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Revolution Medicines — company overview, fundamentals, technicals and alternative data, with a recommendation. See the RVMD AI Score or sign up to read the full thesis.
